Dave Knapp

Correct. In a sense, yes. That's novel, too.

It is. There is a little bit of a middleman... in that they have partnered with telehealth companies to If you don't just go to Eli Lilly, you've got to go to... Well, I guess now it's a little bit different. You can go to anybody and they can prescribe these vials.

It is. There is a little bit of a middleman... in that they have partnered with telehealth companies to If you don't just go to Eli Lilly, you've got to go to... Well, I guess now it's a little bit different. You can go to anybody and they can prescribe these vials.

It is. There is a little bit of a middleman... in that they have partnered with telehealth companies to If you don't just go to Eli Lilly, you've got to go to... Well, I guess now it's a little bit different. You can go to anybody and they can prescribe these vials.

And yes, it comes directly from essentially the manufacturer by way of some... Like Amazon Pharmacy, I think, is offering the Lilly vials now. So there is a distribution element to it, kind of. But yeah, by and large, yeah, it's a novel approach by Big Pharma to go direct to patients. And actually just this week, there was a letter sent from some senators.

And yes, it comes directly from essentially the manufacturer by way of some... Like Amazon Pharmacy, I think, is offering the Lilly vials now. So there is a distribution element to it, kind of. But yeah, by and large, yeah, it's a novel approach by Big Pharma to go direct to patients. And actually just this week, there was a letter sent from some senators.

And yes, it comes directly from essentially the manufacturer by way of some... Like Amazon Pharmacy, I think, is offering the Lilly vials now. So there is a distribution element to it, kind of. But yeah, by and large, yeah, it's a novel approach by Big Pharma to go direct to patients. And actually just this week, there was a letter sent from some senators.

I think it was a bipartisan letter sent to some of the telehealth companies that Lilly Direct and Novocare, that's these two direct-to-consumer programs, and basically gone to their telehealth partners and said, we think there might be a conflict of interest that you're pushing people to your drug. We want to look closer at this. But yes, it did create a novel sort of approach.

I think it was a bipartisan letter sent to some of the telehealth companies that Lilly Direct and Novocare, that's these two direct-to-consumer programs, and basically gone to their telehealth partners and said, we think there might be a conflict of interest that you're pushing people to your drug. We want to look closer at this. But yes, it did create a novel sort of approach.

I think it was a bipartisan letter sent to some of the telehealth companies that Lilly Direct and Novocare, that's these two direct-to-consumer programs, and basically gone to their telehealth partners and said, we think there might be a conflict of interest that you're pushing people to your drug. We want to look closer at this. But yes, it did create a novel sort of approach.

Now, the sad part about it To me, I mean, I think it's great competition, great cheaper drugs for people, great, especially because people on Medicare are just screwed out of this stuff. Medicare is illegal for obesity medication to be covered under Medicare. Now they're getting some secondary...

Now, the sad part about it To me, I mean, I think it's great competition, great cheaper drugs for people, great, especially because people on Medicare are just screwed out of this stuff. Medicare is illegal for obesity medication to be covered under Medicare. Now they're getting some secondary...

Now, the sad part about it To me, I mean, I think it's great competition, great cheaper drugs for people, great, especially because people on Medicare are just screwed out of this stuff. Medicare is illegal for obesity medication to be covered under Medicare. Now they're getting some secondary...

sort of comorbidities that have been approved for cardiovascular disease, heart disease with preserved ejection fraction, sleep apnea, some of these backdoor indications to get you on if you're on Medicare. But by and large, it's illegal for Medicare to cover anti-obesity medicine because going back to the obesity medicines of old, what were they? They were amphetamines, basically.

sort of comorbidities that have been approved for cardiovascular disease, heart disease with preserved ejection fraction, sleep apnea, some of these backdoor indications to get you on if you're on Medicare. But by and large, it's illegal for Medicare to cover anti-obesity medicine because going back to the obesity medicines of old, what were they? They were amphetamines, basically.

sort of comorbidities that have been approved for cardiovascular disease, heart disease with preserved ejection fraction, sleep apnea, some of these backdoor indications to get you on if you're on Medicare. But by and large, it's illegal for Medicare to cover anti-obesity medicine because going back to the obesity medicines of old, what were they? They were amphetamines, basically.

The last thing they wanted to do was give a 75, 80-year-old person an amphetamine. So it's a bit of an archaic law that there are some things trying to correct. The Biden administration moved at the end of their administration to sort of add it, and hopefully the Trump administration picks that up. But There are some positive things.

The last thing they wanted to do was give a 75, 80-year-old person an amphetamine. So it's a bit of an archaic law that there are some things trying to correct. The Biden administration moved at the end of their administration to sort of add it, and hopefully the Trump administration picks that up. But There are some positive things.

The last thing they wanted to do was give a 75, 80-year-old person an amphetamine. So it's a bit of an archaic law that there are some things trying to correct. The Biden administration moved at the end of their administration to sort of add it, and hopefully the Trump administration picks that up. But There are some positive things.

I think the sad part is the PBMs have been squeezing out our local pharmacies for the last 20 years, roughly 17 years. They've been squeezing them out by way of not reimbursing them the appropriate rate. So for example, if you're going to fill your Manjaro at a local pharmacy, chances are they're losing $25 to $50 every time they fill that script.